More good news for zanubrutinib, which received accelerated approval in November 2019 in the US for the treatment of mantle cell lymphoma (MCL) in adult patients who have undergone at least one prior therapy. The supplemental new drug application (sNDA) was submitted by the drug’s manufacturer, BeiGene, based on data from the global phase III ASPEN trial.

Without a centralized scheduling system and 50 states to consider, scheduling a COVID-19 vaccine appointment online isn’t so simple. Thankfully, others with scheduling savvy and a little patience have put together some advice. We invite you to share these tips with your patients struggling to get an appointment and how to handle the technology, processes, and preparation.

In this podcast/article from KevinMD, the implications of long COVID (the symptoms occurring more than three weeks after infection, also known as post-acute COVID syndrome) – specifically focused on post-viral fatigue syndrome (PVFS) – are examined, as the inability to tolerate a glass of wine or a bottle of beer could be an important clue to its true diagnosis.

With 1 in 5 COVID-19 patients receiving a psychiatric diagnosis within 90 days of their COVID diagnosis, it’s obvious the pandemic is wreaking havoc on the population’s mental health, whether its anxiety disorders, insomnia, losing a loved one, losing a job, caring for the sick, or all of the above. Learn what you and your patients can do to protect and manage mental health during these trying times.

Warm autoimmune hemolytic anemia (wAIHA) is the most prevalent form of autoimmune hemolytic anemia (AIHA), accounting for 60% to 70% of all cases. In this special instructional series from Blood (ASH), five patient case studies and commentaries are examined, backed by visual illustrations and new/existing drug treatment tables for wAIHA, wAIHA secondary to CLL, and R/R wAIHA.

This “Clinical Trials & Observations” report from Blood Advances (ASH)  explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.